When was Therini Bio founded?

Therini Bio was founded in 2016 and raised its 1st funding round 4 years after it was founded.

Where is Therini Bio located?

Therini Bio is headquartered in San Francisco, United States.

Is Therini Bio a funded company?

Therini Bio is a funded company, having raised a total of $101M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2020.

When was the latest funding round of Therini Bio?

Therini Bio's latest funding was a $***** Series A round on May 14, 2025, with participation from 9 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.43B in funding in 2026 to date.

Where does Therini Bio rank among its competitors?

Therini Bio ranks 45th amongst 460 active competitors, of which 162 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Therini Bio?

Therini Bio's top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Alchemab secured the most recent funding round in July, 2026.

Therini Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Website: www.therinibio.com/
Email ID: *****@therinibio.com

Key Metrics

Founded Year

2016

Location

San Francisco, United States

Stage

Series A

Total Funding

$101M in 7 rounds

Latest Funding Round

Series A, May 14, 2025, $*****

Investors

MRLV & 14 more

Ranked

45^th among 460 active competitors

Similar Companies

Denali Therapeutics & 570 more

View Therini Bio's full profile

Therini Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Therini Bio, Inc. CIN: 814579978 , United States, Active	Dec 31, 1999	-	5 (As on Dec 31, 2024)	-

Therini Bio has raised a total funding of $101M over 7 rounds. Its first funding round was on 2020. Its latest funding round was a Series A round on May 14, 2025 for $*****. 9 investors participated in its latest round. Therini Bio has 15 institutional investors.

Here is the list of recent funding rounds of Therini Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 14, 2025	6428661	Series A	5896899	3921360	1497670	6324750
Jan 07, 2025	2566354	Grant (prize money)	4015070	5344539	5265685	HHS
Mar 29, 2023	5384611	Conventional Debt	3018371	5261345	8586518	1001451

Access funding benchmarks and valuations. Sign up today!

View details of Therini Bio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Therini Bio include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Therini Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	67/100
5th	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	66/100
6th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	ATW Partners, Sanofi & 6 others	65/100
8th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
9th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
10th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
45th	Therini Bio 2016, San Francisco (United States), Series A	Limited information available	$101M	Sanofi, Lilly & 13 others	55/100